The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 02, 2010

Filed:

Aug. 30, 2004
Applicants:

Venkata P. Palle, Haryana, IN;

Sarala Balachandran, Delhi, IN;

Mohammad Salman, Haryana, IN;

Gagan Kukreja, Delhi, IN;

Nidhi Gupta, Delhi, IN;

Abhijit Ray, Delhi, IN;

Sunanda G. Dastidar, Delhi, IN;

Inventors:

Venkata P. Palle, Haryana, IN;

Sarala Balachandran, Delhi, IN;

Mohammad Salman, Haryana, IN;

Gagan Kukreja, Delhi, IN;

Nidhi Gupta, Delhi, IN;

Abhijit Ray, Delhi, IN;

Sunanda G. Dastidar, Delhi, IN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/422 (2006.01); A61K 31/341 (2006.01); A61K 31/4525 (2006.01); A61K 31/454 (2006.01); A61K 31/496 (2006.01); C07D 261/04 (2006.01); C07D 493/10 (2006.01); C07D 413/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors.


Find Patent Forward Citations

Loading…